Tempus has now raised a total of $520m, after adding $200m to its coffers in a Novo-backed series F round, secured at a $3.1bn valuation.

Pharmaceutical firm Novo Holdings contributed to a $200m series F round for US-based precision medicine developer Tempus yesterday that valued the company at $3.1bn. The round also featured Baillie Gifford, Franklin Templeton, New Enterprise Associates (NEA), Revolution Growth and funds and accounts managed by T. Rowe Price. Founded in 2015, Tempus uses a combination of…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.